COVID-19の突然の発生はすべての市場に大きな影響を与えました。 COVID-19と戦うことに主に焦点が移ったため、他のすべての研究開発は保留されています。 2020年7月、疾病管理予防センター（CDC）はCOVID-19の間に動物を治療するための具体的なガイドラインを獣医専門家に提供しました。 多くの政府機関も、クリニックや病院への緊急かつ重要な訪問を優先することを推奨しています。 さらに、ほとんどの獣医ラボは、OIE（世界動物保健機関）によると、医療施設とCOVID-19検査ラボの世界的な不足を克服するために人間のCOVID-19の検査に積極的に関与しています。 しかし、いくつかの病院やクリニックは、このパンデミック状況下でウイルスの感染を避けるために確実な措置を講じています。 たとえば、Prestige Animal Hospitalsは動物を治療する際に予防措置を講じています。 また、所有者が診断や治療のためにペットを預けることができる「ドロップオフエグザム」プログラムを開始しました。 結果と治療計画は、その後、電話またはメールで議論されます。 その結果、COVID-19の間に獣医訪問が減少したため、コンパニオンアニマルワクチン市場は短期的なわずかな悪影響を経験しています。 したがって、COVID-19は豚ワクチン市場にもわずかな影響を与えると予想されています。

さらに、病気を治療するための新しい豚ワクチンを発見するための主要プレーヤーによる研究開発活動の増加や製品承認の増加が、予測期間中に対象市場の好ましい成長を促進することが期待されています。たとえば、2021年5月に、インド免疫学株式会社（IIL）のブランド名の下で、クラシカルスワインフィーバー（CSF）ワクチンが発売されました。このように、新製品の発売が予測期間中の市場成長を促進すると予想されています。

• 1 イントロダクション

  • 1.1 調査の前提条件と市場の定義

  • 1.2 本調査の範囲

• 2 調査手法

• 3 エグゼクティブサマリー

• 4 市場ダイナミクス

  • 4.1 市場概要

  • 4.2 市場の促進要因

    • 4.2.1 豚肉とゼラチンの需要拡大

    • 4.2.2 豚の疾病の蔓延が増加

    • 4.2.3 ワクチン革新のための研究開発費の増加

  • 4.3 市場の抑制要因

    • 4.3.1 保存状態の維持と取り扱いにかかる高いコスト

    • 4.3.2 ワクチンによる逆反応の可能性

  • 4.4 ポーターのファイブフォース分析

    • 4.4.1 新規参入の脅威

    • 4.4.2 買い手・消費者の交渉力

    • 4.4.3 サプライヤーの交渉力

    • 4.4.4 代替品の脅威

    • 4.4.5 競合・競争状況の激しさ

• 5 市場セグメンテーション（市場規模別、金額、百万米ドル）

  • 5.1 対象疾患別

    • 5.1.1 下痢症

    • 5.1.2 豚インフルエンザ

    • 5.1.3 関節炎

    • 5.1.4 ボルデテラ鼻炎

    • 5.1.5 豚繁殖・呼吸器症候群（PRRS）

    • 5.1.6 豚サーコウイルス関連疾患（PCVAD)

    • 5.1.7 その他の対象疾患

  • 5.2 技術別

    • 5.2.1 不活性化ワクチン

    • 5.2.2 ライブアテンドワクチン

    • 5.2.3 トキソイドワクチン

    • 5.2.4 リコンビナントワクチン

    • 5.2.5 その他

  • 5.3 地域別

    • 5.3.1 北米

      • 5.3.1.1 米国
      • 5.3.1.2 カナダ
      • 5.3.1.3 メキシコ

    • 5.3.2 ヨーロッパ

      • 5.3.2.1 ドイツ
      • 5.3.2.2 英国
      • 5.3.2.3 フランス
      • 5.3.2.4 イタリア
      • 5.3.2.5 スペイン
      • 5.3.2.6 その他のヨーロッパ

    • 5.3.3 アジア太平洋

      • 5.3.3.1 中国
      • 5.3.3.2 日本
      • 5.3.3.3 インド
      • 5.3.3.4 オーストラリア
      • 5.3.3.5 韓国
      • 5.3.3.6 その他のアジア太平洋

    • 5.3.4 中東・アフリカ

      • 5.3.4.1 GCC地域
      • 5.3.4.2 南アフリカ
      • 5.3.4.3 その他の中東・アフリカ

    • 5.3.5 南米

      • 5.3.5.1 ブラジル
      • 5.3.5.2 アルゼンチン
      • 5.3.5.3 その他の南米

• 6 競合情勢

  • 6.1 企業プロファイル

    • 6.1.1 IDT Biologika GmbH

    • 6.1.2 HIPRA

    • 6.1.3 Ceva Sante Animale

    • 6.1.4 Elanco

    • 6.1.5 Arko Laboratories Ltd

    • 6.1.6 Intervet Inc

    • 6.1.7 Merial

    • 6.1.8 Vetoquinol

    • 6.1.9 Zoetis Inc

• 7 市場機会と今後の動向

The Global Porcine Vaccine Market size is estimated at USD 2.05 billion in 2024, and is expected to reach USD 2.95 billion by 2029, growing at a CAGR of 7.5% during the forecast period (2024-2029).

The sudden outbreak of COVID-19 majorly impacted all the markets. With the focus primarily shifted to combat COVID-19, all other research and development are on hold. In July 2020, the Center for Disease Control and Prevention (CDC) provided specific guidelines to veterinary professionals for treating animals during COVID-19. Many government agencies have also recommended prioritizing urgent and emergency visits to clinics and hospitals. Furthermore, most veterinary laboratories are actively involved in testing COVID-19 in humans to overcome the global shortage of healthcare facilities and COVID-19 testing laboratories, according to the OIE (World Organization for Animal Health). However, some hospitals and clinics are taking definite measures to avoid the transmission of the virus during this pandemic situation. Prestige Animal Hospitals, for example, has taken precautionary measures when treating animals. It also launched the 'Drop Off Exams' program, which allows owners to drop off their pets for diagnosis or treatment. The results and treatment plans are then discussed through a phone call/e-mail. As a result, the companion animal vaccine market is experiencing a slight short-term negative impact, owing to lower veterinary visits during COVID-19. Thus, COVID-19 is expected to impact the porcine vaccine market slightly.

Additionally, the growing R&D activities by the key players for discovering novel porcine vaccines to treat diseases and rising product approvals are expected to aid in the positive growth of the studied market over the forecast period. For instance, in May 2021, the Classical Swine Fever (CSF) vaccine was launched under the Raksha Class by Indian Immunologicals Limited (IIL) brand name. Thus, rising product launches anticipated market growth over the forecast period.

According to the Congress Budget Office report in April 2021, the pharmaceutical industry spent USD 83 billion on research and development. These costs were paid for various activities, including discovering and testing new drugs, developing incremental innovations like product extensions, and conducting clinical trials for safety monitoring or marketing purposes. Thus rising in R&D spending boosts the market over the forecast period.

PRRS (Porcine Reproductive and Respiratory Syndrome) is still a common disease in pig farms, causing financial losses due to its adverse effects on reproduction, growth, and clinical illness. As a result, market innovation to meet customer demand has been ongoing. For example, in April 2021, Ahmedabad-based company Hester Bioscience got the right to commercially produce classical swine fever and sheep pox vaccines in India. Scientists develop these two vaccines from the Indian Veterinary Research Institute (IVRI), Izatnagar, under the Indian Council of Agricultural Research (ICAR). Also, in April 2021, the Argentine laboratory Vetanco partnered with Pharmgate Animal Health to distribute the Circo/MycoGard vaccine in Argentina and Latin America. The vaccine protects pigs against both PCV-2 and Mycoplasma hyopneumoniae.

Thus, owing to the abovementioned factors, the market is expected to show growth over the forecast period. However, high expenses of maintaining and handling storage conditions and chance of reverse reaction from vaccines significantly hinder the market's growth.

Porcine Vaccines Market Trends

Porcine Circovirus Associated Disease is Expected to Witness a Healthy Growth

PCV (Porcine Circovirus) is the smallest non-enveloped, single-stranded DNA virus, which replicates autonomously in eukaryotic cells, using the host polymerase for genome amplification. PCV can be spread through direct contact with an infected pig. PCV2 is the single-stranded DNA (ssDNA) virus with the highest mutation and recombination rate of all single-stranded DNA (ssDNA) viruses. PCV is one of the most important infectious agents affecting pig productivity worldwide.

Furthermore, according to Henna's article published in MDPI Viruses in January 2021, the global prevalence and status of PCV have resulted in a seropositivity rate of 20-80% in pigs, as well as a very high incidence rate of 60%, with a culling rate of 40% in severely affected pig farms.

Commercially available PCVAD vaccines can be of many types, mainly based upon the dosage, packaging size, age of the pig it is used on, and virus type. Some of the major brands manufacturing and selling porcine vaccines for PCVAD, globally, are Boehringer Ingelheim, Merck, and Zoetis, among others. The first FLEX Family swine vaccine for PCV2 protection in a single injection was Ingelvac CircoFLEX, by Boehringer Ingelheim. Hence, it is one of the revolutionary PCV2 vaccines on the market.

Thus, the segment is anticipated to witness significant growth over the forecast period due to the abovementioned factors.

North America Holds a Significant Market Share

Increasing pork consumption, the growing prevalence of various swine diseases, and rising per capita animal healthcare expenditure are the factors the United States is expected to retain its large market share.

In the United States, advancements in vaccine development include the development of live vector vaccines, non-replicating recombinant antigen vaccines, nucleic acid-mediated vaccines, and live-gene-deleted vaccines. Moreover, technological advances in the vaccine field and well-established healthcare infrastructure are also considerably fueling the regional market's growth. For instance, in March 2022, Boehringer Ingelheim launched the porcine parvovirus vaccine ReproCyc ParvoFLEX which provides safe, efficacious protection for healthy sows and gilts six months of age or older against reproductive failure caused by porcine parvovirus.

Furthermore, according to the Agricultural Economic Insights (AEI) report, meat consumption in the United States increased in 2020 when studied from 1970 to 2020. Although poultry, beef, and pork consumption pattern broadly vary, it increases the risk of swine diseases.

Thus, the market is expected to witness significant growth during the forecast period due to the abovementioned factors.

Porcine Vaccines Industry Overview

The porcine vaccines market is fairly competitive and consists of several major players including Hipra, Zoetis, Elanco Inc, Boehringer Ingelheim, and Vetoquinol. Most of these major players enjoy a global presence and are facing intense competition in emerging economies. The emerging countries are becoming hotspots for significant competition, due to a rapidly expanding market size, fueled by rising concerns over food safety and the increasing adoption of companion as well as farm animals.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

• 1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition

  • 1.2 Scope of the Study

• 2 RESEARCH METHODOLOGY

• 3 EXECUTIVE SUMMARY

• 4 MARKET DYNAMICS

  • 4.1 Market Overview

  • 4.2 Market Drivers

    • 4.2.1 Growth in Demand for Pork and Gelatin

    • 4.2.2 Rise in Prevalence of Swine Diseases

    • 4.2.3 Increase in R&D Expenditure for Innovation of Vaccines

  • 4.3 Market Restraints

    • 4.3.1 High Expenses of Maintaining and Handling Storage Conditions

    • 4.3.2 Chance of Reverse Reaction from Vaccines

  • 4.4 Porter's Five Force Analysis

    • 4.4.1 Threat of New Entrants

    • 4.4.2 Bargaining Power of Buyers/Consumers

    • 4.4.3 Bargaining Power of Suppliers

    • 4.4.4 Threat of Substitute Products

    • 4.4.5 Intensity of Competitive Rivalry

• 5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Target Disease

    • 5.1.1 Diarrhea

    • 5.1.2 Swine Influenza

    • 5.1.3 Arthritis

    • 5.1.4 Bordetella Rhinitis

    • 5.1.5 Porcine Reproductive and Respiratory Syndrome (PRRS)

    • 5.1.6 Porcine Circovirus Associated Disease (PCVAD)

    • 5.1.7 Other Target Diseases

  • 5.2 By Technology

    • 5.2.1 Inactivated Vaccines

    • 5.2.2 Live Attenuated Vaccines

    • 5.2.3 Toxoid Vaccines

    • 5.2.4 Recombinant Vaccines

    • 5.2.5 Others

  • 5.3 Geography

    • 5.3.1 North America

      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico

    • 5.3.2 Europe

      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe

    • 5.3.3 Asia-Pacific

      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific

    • 5.3.4 Middle-East and Africa

      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East and Africa

    • 5.3.5 South America

      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

• 6 COMPETITIVE LANDSCAPE

  • 6.1 COMPANY PROFILES

    • 6.1.1 IDT Biologika GmbH

    • 6.1.2 HIPRA

    • 6.1.3 Ceva Sante Animale

    • 6.1.4 Elanco

    • 6.1.5 Arko Laboratories Ltd

    • 6.1.6 Intervet Inc

    • 6.1.7 Merial

    • 6.1.8 Vetoquinol

    • 6.1.9 Zoetis Inc

• 7 MARKET OPPORTUNITIES AND FUTURE TRENDS